Postpartum weight retention in women with polycystic ovary syndrome

Lee, Iris; Alur-Gupta, Snigdha; Gallop, Robert; Dokras, Anuja

doi:10.1016/j.ajog.2020.07.033

Cited by 3 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women of childbearing age [1] . It is characterized by chronic ovulation dysfunction and hyperandrogenemia, affecting 3.84% to 10.11% of women of childbearing age worldwide [2,3] .…”

Section: Introductionmentioning

confidence: 99%

“…Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women of childbearing age. [1] It is characterized by chronic ovulation dysfunction and hyperandrogenemia, affecting 3.84% to 10.11% of women of childbearing age worldwide. [2,3] PCOS is often accompanied by risks of abdominal obesity, insulin resistance, metabolic disorders, and cardiovascular disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome

Liu¹,

Shao²,

Xie³

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: Several previous randomized controlled trials (RCTs) evaluated the efficacy of metformin combined with simvastatin in the treatment of polycystic ovary syndrome (PCOS), yet the results of the researches are not consistent. It is necessary to conduct a meta-analysis to explore the efficacy and safety of metformin combined with simvastatin in the treatment of PCOS, to provide evidence supports for the treatment of PCOS.Methods: We searched PubMed, EMbase, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and Chinese biomedical literature databases online to identify the RCTs evaluating the efficacy of metformin combined with simvastatin in the treatment of PCOS. Standardized mean difference (SMD) and 95% confidence interval (95% CI) were calculated to evaluate the synthesized effects.Results: Nine RCTs with a total of 746 PCOS patients were included. The synthesized results indicated that the combined use of metformin and simvastatin are more beneficial to reduce the total cholesterol (SMD -2.66, 95% CI -3.65 to -1.66), triglycerides (SMD -1.25, 95% CI -2.02 to -0.49), low density lipoprotein (SMD -2.91, 95% CI -3.98 to -1.84), testosterone (SMD -0.64, 95% CI -1.13 to -0.15), fasting insulin (SMD -1.17, 95% CI -2.09 to -0.26) than metformin alone treatment in PCOS patients (all P < .001), and there was no significant difference in the high density lipoprotein (SMD -0.05, 95% CI -0.56-0.46), luteinizing hormone (SMD -0.58, 95% CI -1.66 to -0.50), follicle stimulating hormone (SMD 0.41, 95% CI -0.78-1.59), prolactin (SMD -1.38, 95% CI -2.93-0.17), fasting blood sugar (SMD 0.23, 95% CI -0.52-0.97), and insulin sensitivity index (SMD -0.17, 95% CI -0.48-0.15) between experimental and control groups (all P > .05).Conclusions: Metformin combined with simvastatin is superior to metformin alone in the treatment of PCOS patients with more advantages in improving the levels of sex hormones, blood lipids, and blood sugar. However, the safety of this therapy still needs to be further explored in clinical studies with high-quality and large samples. Abbreviations: 95% CI = 95% confidence interval, FBS = fasting blood sugar, FIN = fasting insulin, FSH = follicle stimulating hormone, HDL = high density lipoprotein, LDL = low density lipoprotein, OR = odds ratio, PCOS = polycystic ovary syndrome, RCT = randomized controlled trial, SMD = standardized mean difference, T = testosterone, TC = total cholesterol, TG = triglycerides.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome

Liu¹,

Shao²,

Xie³

et al. 2021

Medicine

View full text Add to dashboard Cite

show abstract

The effect of a low carbohydrate ketogenic diet with or without exercise on postpartum weight retention, metabolic profile and physical activity performance in postpartum mice

Hsu

Huang

Lin

2022

The Journal of Nutritional Biochemistry

View full text Add to dashboard Cite

Polycystic ovary syndrome

Planey,

Grosel

2024

Jaapa

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a complex, heterogeneous reproductive endocrinopathy affecting 8% to 13% of women in their reproductive years. PCOS has a vast array of clinical manifestations, including metabolic complications, biochemical and phenotypical hyperandrogenism, menstrual cycle dysfunction, and anovulation resulting in infertility. Understanding the relationship of the disorder's pathophysiologic and clinical manifestations is key to successfully managing patients with PCOS. Patients may have different prenatal, perinatal, and postnatal experiences than those who do not have PCOS, and may require a higher level of care or treatment plan adjustments.

show abstract

Postpartum weight retention in women with polycystic ovary syndrome

Cited by 3 publications

References 41 publications

The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome

The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome

The effect of a low carbohydrate ketogenic diet with or without exercise on postpartum weight retention, metabolic profile and physical activity performance in postpartum mice

Polycystic ovary syndrome

Contact Info

Product

Resources

About